Tests a smart insulin pen with glucose-sensor coaching in diabetes
Tests a smart insulin pen with coaching in adults with type 1 or 2 diabetes.
Key facts
- Who runs it
- G2e Co., Ltd
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes
- Status
- Not yet recruiting
- People taking part
- 152 people, planned
- Started
- Jun 2025
- Expected to end
- Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Smart Coaching Insulin Pen
- Record updated
- 4 June 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 19 to 75 with type 1 or type 2 diabetes who use multiple daily insulin injections and have HbA1c of 7.5% (58 mmol/mol) to 12.0% (108 mmol/mol).
- Age
- 19 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Type 1 or type 2 diabetes diagnosed at least 1 year before screening. HbA1c of 7.5% (58 mmol/mol) to 12.0% (108 mmol/mol) at screening.
- Earlier treatment
- Must have used multiple daily insulin injections (MDI) for at least 3 months before screening, for example long-acting insulin plus rapid- or short-acting insulin, or mixed insulin at least 3 times per day.
- Biomarker or test result
- HbA1c of 7.5% (58 mmol/mol) to 12.0% (108 mmol/mol) at screening.
Main reasons for not taking part
- Diabetes caused by removal of part of the pancreas
- Corticosteroids above a prednisolone-equivalent dose of 5 mg/day within 3 months before screening (stable dose for at least 3 months may be allowed)
- eGFR below 15 mL/min at screening or receiving dialysis
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age between 19 and 75 years old
- Diagnosis of type 1 or type 2 diabetes for at least 1 year prior to screening
- Continuous use of MDI therapy for at least 3 months prior to screening, defined as one of the following regimens:; Long-acting insulin plus rapid-/short-acting insulin; Mixed insulin (e.g., insulin aspart/insulin degludec) plus rapid-/short-acting insulin; Mixed insulin ≥3 times per day
- HbA1c of 7.5% to 12.0% at screening
Who cannot take part
- Use of corticosteroids exceeding a prednisolone-equivalent dose of 5 mg/day within 3 months prior to screening (Subjects on a stable dose for ≥3 months prior to screening may be eligible)
- Diabetes mellitus secondary to pancreatic resection
- eGFR <15 mL/min at screening or those receiving dialysis
- Pregnant or lactating women
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 75 years old?
Where in South Korea
- Samsung Medical CenterSeoul, South KoreaContact: SANGMAN JINNot yet recruiting
About the trial
What the trial wants to find out
A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes
The 2 groups in the trial
- Investigational GroupTreatment being tested
Basal and bolus insulin injection using an electric smart insulin pen (DIA:CONN P8); equipped with a Setup-wizard, CGM-based Advanced insulin injection Coaching and a Bolus calculator \- Providing education on Carb Counting(carbohydrate measurement) and Methods for adjusting insulin bolus calculator
Treatment: Smart Coaching Insulin Pen
- Control groupNo study treatment, for comparison
Basal and bolus insulin injection using only the injection and recording functions of DIA:CONN P8 \- Subjects manually enter and inject their insulin doses without using the bolus calculator or coaching functions
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Open Label, Randomized, Comparative Confirmatory Study to Evaluate the Efficacy and Safety of Electric Smart Insulin Pen (DIA:CONN P8) Including Setup Wizard, Advanced Insulin Injection Coaching and Bolus Calculator With Analysis Function Based on Continuous Glucose Monitoring Data in Patients With Type 1 or Type 2 Diabetes Mellitus Under Multiple Dose Insulin Therapy
- Plain-language title
- Tests a smart insulin pen with glucose-sensor coaching in diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07004153, who can take part
- Publications
- Efficacy and Safety of Stage 5 Connected Insulin Pens in Type 1 or Type 2 Diabetes: Randomized Controlled Trial Protocol (SMART-5 Study).Endocrinology and metabolism (Seoul, Korea), 2026
- Record updated
- 4 June 2025